Firazyr 30 Mg 30 mg Solution for Injection
PDF Leaflet Revision Date: 04 August 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Symptomatic treatment of acute attacks of hereditary angioedema (HAE).
Dosage (summary)
Adults: 30 mg subcutaneously; may repeat after 6 hours if needed (max 3 injections/24 hours).
Onset of Action / Duration
Onset: 1-2 hours, Duration: 6-8 hours
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Use in pregnancy only if benefits outweigh risks; avoid breastfeeding for 12 hours post-treatment.
Key Drug Interactions
- ACE inhibitors contraindicated
Contraindications
- Hypersensitivity to icatibant or excipients
Common side effects
- Injection site reactions
- Dizziness
- Nausea
Counselling Points
- Train in injection technique
- Seek medical advice if symptoms persist
- Avoid driving if feeling dizzy
Serious warnings
- Monitor patients with laryngeal attacks
- Caution in ischemic heart disease
Important Disclaimer
The Firazyr 30 Mg 30 mg Solution for Injection professional information leaflet below is the property of Takeda and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
